Stratagene, Hycor, Sigma-Aldrich, Procognia, BD Bioscience, PerkinElmer | GenomeWeb

Hycor Acquisition, QPCR Sales Boost Stratagene’s Q3 Revenues

Stratagene on Tuesday reported a 37-percent increase in third-quarter revenues and nearly tripled its quarterly net income.

Stratagene’s revenues increased to $23.1 million for the quarter from $16.9 million in the third quarter of 2003. The company’s Hycor subsidiary, which it acquired in June, was responsible for $5.6 million of the increase in revenues for the quarter, Stratagene said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.